Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07219758

RECANA OUS – Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK)

RECANA OUS – Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK) — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07219758.

📅 25 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07219758
Sponsor
Intervene, Inc.
Start
2025-10-18
ClinicaliQ Trial Snapshot
  • RECANA OUS – Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK) — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07219758.
  • The goal of this clinical investigation is to learn if the Recana Thrombectomy Catheter System can treat chronic venous obstruction and occlusion in participants with symptomatic post-thrombotic venous inflow/outflow obstruction. The main questions the clinical investigation aims to answer are: 1. primary….
  • Sponsor: Intervene, Inc.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical investigation is to learn if the Recana Thrombectomy Catheter System can treat chronic venous obstruction and occlusion in participants with symptomatic post-thrombotic venous inflow/outflow obstruction. The main questions the clinical investigation aims to answer are: 1. primary safety endpoint: procedural events defined as the rates of all adverse events occurring up to 30 days post-index procedure 2. primary efficacy endpoint: percent (%) lumen gain during the index procedure, which is measured using intravascular ultrasound (IVUS) at the time of the procedure (perioperative/periprocedural) Participants are screened…

Eligibility Snapshot
  • : 1. Provision of signed and dated informed consent form;
  • Participant is 18 years of age and older; 3. Neurologically stable; 4. Ambulatory; 5. Symptomatic chronic venous insuSciency (CVI), with edema or pain, (CEAP classification of C3 or greater); 6. Flow-limiting venous outflow obstruction (>50%) within the intended target sites, defined by (a) a common femoral vein continuous waveform without respiratory variation on duplex ultrasound, or, (b) complete occlusion of any part of the iliofemoral tract as diagnosed on baseline duplex or axial imaging per local protocol; and 7. Target treatment IVC/Common Iliac confluence to the deep veins above the knee.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
There’s a reason child vaccination rates are falling – and it’s not social media
Respiratory / COPD / Asthma · BBC Health · 03 Aug 2026
Vaccination rates declining across UK: Child immunisation coverage is falling below safe thresholds needed for herd immunity, creating vulnerability to vaccine-preventable disease…
View brief →
Clinical Brief
Over one million children referred for mental healthcare – with anxiety the main reason
Respiratory / COPD / Asthma · BBC Health · 29 Jun 2026
Over one million children in England have been referred for mental healthcare, with anxiety as the leading presenting complaint, indicating a substantial…
View brief →
Guideline
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Respiratory / COPD / Asthma · 17 Jun 2026
Mepolizumab is recommended for patients with uncontrolled COPD and blood eosinophils ≥100 cells/μL; check eosinophil levels before initiating treatment as this is…
View guideline →
Clinical Brief
‘It’s not a nice world to bring children into’: Births fall to the lowest level in 50 years
Respiratory / COPD / Asthma · BBC Health · 27 May 2026
Record low fertility rates: Live births in England and Wales have fallen to their lowest level in 50 years, reflecting significant demographic…
View brief →
Clinical Brief
What is postpartum psychosis and why is it central in the Lindsay Clancy trial?
Respiratory / COPD / Asthma · BBC Health · 19 Aug 2026
Postpartum psychosis is a rare but severe psychiatric emergency occurring in 1-2 per 1,000 deliveries, characterised by delusions, hallucinations, and disorganised thinking…
View brief →
Clinical Brief
Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision
Respiratory / COPD / Asthma · MHRA · 20 May 2026
Amiodarone carries serious risks of pulmonary, hepatic, and thyroid toxicity requiring regular patient monitoring and supervision throughout treatment Healthcare professionals must ensure…
View brief →